GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.Luke will succeed the current CEO, Dame Emma Walmsley.He joined GSK in 2017 and is currently Chief Commercial Officer, with worldwide responsibility for medicines and vaccines.He has been instrumental in building GSK’s specialty medicines portfolio, notably in oncology and respiratory.Luke has previously worked at senior levels in the US, Europe, and Asia, at ...